Clinical Cancer Research, Vol 3, Issue 11 2005-2015, Copyright © 1997 by American Association for Cancer Research

ARTICLES

A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors

G Giaccone, SC Linn, J Welink, G Catimel, H Stieltjes, WJ van der Vijgh, C Eeltink, JB Vermorken and HM Pinedo
Department of Medical Oncology, University Hospital Vrije, HV 1081 Amsterdam, The Netherlands.

Forty-two patients with advanced solid tumors were entered into a dose-finding study of the combination of doxorubicin with the cyclosporin analogue SDZ PSC 833 (PSC), given by oral route. Patients received PSC at escalating doses, ranging from 2.5 to 25 mg/kg/day, for 5 days, in doses given every 12 h. Doxorubicin was given by i.v. push on day 3 of PSC administration, 4 h after the morning dose of PSC. Pharmacokinetic analyses of PSC and doxorubicin were performed. A total of 38 patients received a combination of PSC and doxorubicin, and 27 received doxorubicin alone in the first course. The major toxicity of the combination was hematological and was significantly more severe than that with doxorubicin alone; severe myelosuppression was already observed at the first PSC dose level, which required doxorubicin dose reduction from 50 to 35 mg/m2. At all dose levels of PSC, up to 17.5 mg/kg/day, there were at least two patients with grade 3 or 4 hematological toxicity, which was manageable in less heavily pretreated patients. A further PSC dose escalation was performed to 25 mg/kg/day, together with doxorubicin, at a further reduced dose of 20 mg/m2. At this dose, central nervous system toxicity became the most relevant side effect. The increase of toxicity in the combined treatment was supported by a significant increase of the area under the plasma concentration-time curve to infinity of doxorubicin (54%) and a 10-fold increase of the area under the plasma concentration-time curve to infinity of doxorubicinol. The pharmacological interaction was not dependent on the plasma concentration of PSC. The total body clearance of doxorubicin decreased by 30%. PSC plasma concentrations of >1 microM at the time of doxorubicin administration were, in general, found at a dose of 7.5 mg/kg/day or higher. One patient had a partial response. In conclusion, PSC plasma concentrations that can revert multidrug resistance in experimental models could be achieved in patients who have solid tumors and who are treated with doxorubicin. However, a marked pharmacological interaction was found between doxorubicin and PSC, which led to substantial increase in hematological toxicity and required marked reduction of the doxorubicin dose. Further study of PSC may be warranted, in association with the investigation of P-glycoprotein expression and concentration of drugs in the tumor tissues.

This article has been cited by other articles:

				V. Dieras, J. Bonneterre, V. Laurence, M. Degardin, J.-Y. Pierga, M.-E. Bonneterre, S. Marreaud, D. Lacombe, and P. Fumoleau Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies Clin. Cancer Res., September 1, 2005; 11(17): 6256 - 6260. [Abstract] [Full Text] [PDF]

				P. M. Fracasso, L. J. Goldstein, D. P. de Alwis, J. S. Rader, M. A. Arquette, S. A. Goodner, L. P. Wright, C. L. Fears, R. J. Gazak, V. A. M. Andre, et al. Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies Clin. Cancer Res., November 1, 2004; 10(21): 7220 - 7228. [Abstract] [Full Text] [PDF]

				A. Sandler, M. Gordon, D. P. de Alwis, I. Pouliquen, L. Green, P. Marder, A. Chaudhary, K. Fife, L. Battiato, C. Sweeney, et al. A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy Clin. Cancer Res., May 15, 2004; 10(10): 3265 - 3272. [Abstract] [Full Text] [PDF]

				E. H. Rubin, D. P. de Alwis, I. Pouliquen, L. Green, P. Marder, Y. Lin, R. Musanti, S. L. Grospe, S. L. Smith, D. L. Toppmeyer, et al. A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar.3HCl Trihydrochloride (LY335979), Administered Orally in Combination with Doxorubicin in Patients with Advanced Malignancies Clin. Cancer Res., December 1, 2002; 8(12): 3710 - 3717. [Abstract] [Full Text] [PDF]

				M. R. Baer, S. L. George, R. K. Dodge, K. L. O'Loughlin, H. Minderman, M. A. Caligiuri, J. Anastasi, B. L. Powell, J. E. Kolitz, C. A. Schiffer, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood, July 30, 2002; 100(4): 1224 - 1232. [Abstract] [Full Text] [PDF]

				M. Baekelandt, G. Lehne, C. G. Trope, I. Szanto, P. Pfeiffer, B. Gustavssson, and G. B. Kristensen Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian Cancer J. Clin. Oncol., June 15, 2001; 19(12): 2983 - 2993. [Abstract] [Full Text] [PDF]

				R. Advani, G. A. Fisher, B. L. Lum, J. Hausdorff, J. Halsey, M. Litchman, and B. I. Sikic A Phase I Trial of Doxorubicin, Paclitaxel, and Valspodar (PSC 833), a Modulator of Multidrug Resistance Clin. Cancer Res., May 1, 2001; 7(5): 1221 - 1229. [Abstract] [Full Text]

				R. Dorr, C. Karanes, C. Spier, T. Grogan, J. Greer, J. Moore, B. Weinberger, G. Schiller, T. Pearce, M. Litchman, et al. Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia J. Clin. Oncol., March 15, 2001; 19(6): 1589 - 1599. [Abstract] [Full Text] [PDF]

				I. Chico, M. H. Kang, R. Bergan, J. Abraham, S. Bakke, B. Meadows, A. Rutt, R. Robey, P. Choyke, M. Merino, et al. Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833 J. Clin. Oncol., February 1, 2001; 19(3): 832 - 842. [Abstract] [Full Text] [PDF]

				A. Plonowski, A. V. Schally, A. Nagy, H. Kiaris, F. Hebert, and G. Halmos Inhibition of Metastatic Renal Cell Carcinomas Expressing Somatostatin Receptors by a Targeted Cytotoxic Analogue of Somatostatin AN-238 Cancer Res., June 1, 2000; 60(11): 2996 - 3001. [Abstract] [Full Text] [PDF]

				G. Y. Kwei, R. F. Alvaro, Q. Chen, H. J. Jenkins, C. E. A. C. Hop, C. A. Keohane, V. T. Ly, J. R. Strauss, R. W. Wang, Z. Wang, et al. Disposition of Ivermectin and Cyclosporin A in CF-1 Mice Deficient in mdr1a P-Glycoprotein Drug Metab. Dispos., May 1, 1999; 27(5): 581 - 587. [Abstract] [Full Text]